[1] 冯骁,仓顺东.中国肺癌筛查标准(T/CPMA 013-2020)解读[J].中华实用诊断与治疗杂志,2021,35(3):217-219. DOI:10.13507/j.issn.1674-3474.2021.03.001.
[2] Yamada Y, Tamura T, Yamamoto Y, et al. Treatment of patients with non-small-cell lung cancer with uncommon EGFR mutations in clinical practice[J]. Anticancer Res, 2020, 40(10):5757-5764. DOI: 10.21873/anticanres. 14592.
[3] 田果平.脾多肽注射液联合培美曲塞对一线靶向治疗耐药的非小细胞肺癌的疗效及其对血清前梯度蛋白2、基质金属蛋白酶-9水平的影响[J].肿瘤基础与临床,2020,33(3):201-204.
[4] 张琪,程渊,张蒙,等.表皮生长因子受体20号外显子插入突变晚期非小细胞肺癌的治疗现状[J].中华医学杂志,2022,102(26):2054-2062. DOI:10.3760/cma.j.cn112137- 20211018-02302.
[5] 赵亚琪,王盼,张诗.驱动基因阴性晚期非小细胞肺癌最佳免疫治疗方案研究进展[J].肿瘤学杂志,2022,28(6):443-451.
[6] Kari C, Jean-Paul S, John JC, 等.国际肺癌研究会分期项目采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期[J].中国肺癌杂志,2010,13(1):9-18. DOI:10.3779/j.issn.1009-3419.2010.01.02.
[7] 剑男,杨邵瑜,陈雪琴,等.2022年第3版«NCCN非小细胞肺癌临床实践指南»更新解读[J].实用肿瘤杂志,2022,37(3):197-204. DOI:10.13267/j.cnki.syzlzz.2022.033.
[8] 毛雨秋,陈良峰.标准化疗方案结合阿帕替尼治疗驱动基因阴性晚期非小细胞肺癌的疗效观察[J].实用中西医结合临床,2021,21(1):94-96. DOI:10.13638/j.issn.1671-4040. 2021.01.045.
[9] Sjoquist KM, Martin A, Pavlakis N, et al. Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer[J]. J Cancer Res Clin Oncol, 2023, 149(8):4959-4965. DOI: 10.1007/s00432- 022-04404-4.
[10] Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1):90-92. DOI: 10.1016/j.ad.2019.05.009.
[11] Ma Y, Zong H, Wang J, et al. Efficacy and safety of apatinib in treatment of gastric cancer: a real-world study[J].JCO, 2021, 39(3_suppl):182. DOI:10.1200/JCO.2021.39.3_suppl.182.
[12] 田琪.非小细胞肺癌免疫治疗的影像学研究进展[J].放射学实践,2023,38(2):230-234. DOI:10.13609/j.cnki.1000- 0313.2023.02.021.
[13] Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2021, 18(9):547-557. DOI: 10.1038/s41571-021-00501-4.
[14] 赵文华,曾爱屏.免疫检查点抑制剂治疗驱动基因阴性非小细胞肺癌脑转移的研究进展[J].广西医科大学学报,2022,39(8):1326-1333. DOI:10.16190/j.cnki.45-1211/r.2022. 08.023.
[15] 徐璐,黄栎有,王延花等.PD-1抑制剂联合脑部放疗治疗驱动基因阴性非小细胞肺癌脑转移的疗效及安全性分析[J].实用医学杂志,2022,38(24):3100-3105.
[16] Del Conte A, De Carlo E, Bertoli E, et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications[J]. Int J Mol Sci, 2022, 23(12):6832. DOI: 10.3390/ijms23126832.
[17] Xu R, Wu J, Zhang X, et al. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization[J]. Pharmacol Res, 2020, 152:104623. DOI: 10.1016/j.phrs.2019.104623.
[18] 王玥,杨志国,王艳华,等.黄芪多糖与人参多糖免疫调节作用的研究进展[J].食品安全质量检测学报,2021,12(3):891-897. DOI:10.19812/j.cnki.jfsq11-5956/ts.2021. 03.010.
[19] 邓逸菲,李明达,刘端勇,等.补中益气汤的免疫药理及其临床应用研究进展[J].中医临床研究,2023,15(7):68-72. DOI:10.3969/j.issn.1674-7860.2023.07.015.
[20] 吴寅飞,周娟,叶伶云,等.驱动基因阴性晚期非小细胞肺癌脑转移免疫微环境及免疫治疗的研究进展[J].中国肿瘤临床,2021,48(24):1253-1258. DOI:10.12354/j.issn.1000- 8179.2021.20201752.
[21] 牟琪瑞,付权泽,刘春英,等.补中益气汤含药血清干预A549/DDP细胞Wnt/β-catenin信号通路改善顺铂耐药的机制研究[J].时珍国医国药,2021,32(8):1818-1821. DOI:10.3969/j.issn.1008-0805.2021.08.07.
[22] 热娜古丽·艾则孜,付艳丽,何娜娜,等.补中益气汤对中晚期恶性肿瘤患者化疗后不良反应的影响[J].河南中医,2023,43(2):238-241. DOI:10.16367/j.issn.1003-5028. 2023.02.0047.
|